ZIKA-001: Safety and Immunogenicity of an Engineered DNA Vaccine Against ZIKA virus infection

BACKGROUND: While Zika virus (ZIKV) infection is typically self-limited, congenital birth defects and Guillain-Barré syndrome are well-described. There are no therapies or vaccines against ZIKV infection. METHODS: ZIKA-001 is a phase I, open label, clinical trial designed to evaluate the safety, sid...

Descripción completa

Detalles Bibliográficos
Autores principales: Tebas, Pablo, Roberts, Christine C, Muthumani, Kar, Reuschel, Emma, White, Scott, Khan, Amir S, Racine, Trina, Choi, Hyeree, Zaidi, Faraz, Boyer, Jean, Kudchodkar, Sagar, Park, Young K, Trottier, Sylvie, Remigio, Celine, Krieger, Diane, Kobinger, Gary P, Weiner, David, Maslow, Joel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631827/
http://dx.doi.org/10.1093/ofid/ofx163.693

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631827/
http://dx.doi.org/10.1093/ofid/ofx163.693

Ejemplares similares